每(mei)經AI快訊，7月1日(ri)，九洲(zhou)藥(yao)(yao)(yao)業（603456.SH）公(gong)(gong)(gong)告稱，公(gong)(gong)(gong)司(si)控股子公(gong)(gong)(gong)司(si)浙(zhe)江九洲(zhou)生物醫藥(yao)(yao)(yao)有限公(gong)(gong)(gong)司(si)收到(dao)國(guo)家藥(yao)(yao)(yao)品(pin)監督管(guan)理(li)局核(he)準(zhun)簽發(fa)的(de)枸(gou)(gou)櫞酸(suan)西地(di)(di)那非口崩(beng)片(pian)的(de)《藥(yao)(yao)(yao)品(pin)注(zhu)(zhu)冊(ce)證(zheng)書(shu)(shu)》。該(gai)藥(yao)(yao)(yao)品(pin)為輝瑞基于以患者(zhe)為中(zhong)心開(kai)發(fa)的(de)西地(di)(di)那非迭代(dai)劑型，2019年(nian)在中(zhong)國(guo)批(pi)準(zhun)進口。目前國(guo)內(nei)獲得該(gai)藥(yao)(yao)(yao)品(pin)注(zhu)(zhu)冊(ce)證(zheng)書(shu)(shu)的(de)廠家主要為四川(chuan)科倫(lun)藥(yao)(yao)(yao)業股份有限公(gong)(gong)(gong)司(si)、廣東泰恩康醫藥(yao)(yao)(yao)股份有限公(gong)(gong)(gong)司(si)等(deng)。根據公(gong)(gong)(gong)開(kai)數據，2023年(nian)國(guo)內(nei)醫療市場與零售(shou)市場枸(gou)(gou)櫞酸(suan)西地(di)(di)那非片(pian)銷(xiao)售(shou)總(zong)額(e)（終端價）為52.17億元人民幣。九洲(zhou)藥(yao)(yao)(yao)業已在枸(gou)(gou)櫞酸(suan)西地(di)(di)那非口崩(beng)片(pian)累計(ji)研發(fa)投入約為人民幣1352萬元。本次取得該(gai)藥(yao)(yao)(yao)品(pin)注(zhu)(zhu)冊(ce)證(zheng)書(shu)(shu)，進一步豐(feng)富公(gong)(gong)(gong)司(si)產(chan)(chan)品(pin)管(guan)線，有助于提升(sheng)公(gong)(gong)(gong)司(si)產(chan)(chan)品(pin)的(de)市場競爭力，但短期內(nei)不(bu)會對公(gong)(gong)(gong)司(si)業績(ji)產(chan)(chan)生重大影(ying)響。